As a follow-up to MSAA’s online article, “Zinbryta® Withdrawn from Marketplace,” MSAA is alerting individuals taking Zinbryta® (daclizumab) to additional information on the withdrawal. On March 14, 2018, the United States Food and Drug Administration (FDA) issued a press release to assist with the withdrawal of Zinbryta from the market in the United States. They […]

On March 2, 2018, Biogen and AbbVie announced the voluntary withdrawal of their MS medication, Zinbryta® (daclizumab), due to new safety concerns. Eight cases of inflammatory encephalitis and meningoencephalitis – both forms of brain inflammation – have been reported in two European countries. According to Reuters, seven cases of these serious brain disorders occurred in […]

Sandoz, a Novartis division, announced today that the United States Food and Drug Administration (FDA) approved Glatopa® (glatiramer acetate injection) at a three-times weekly 40-mg dose. This generic version of Copaxone®, a disease-modifying therapy (DMT) approved for the treatment of relapsing forms of multiple sclerosis (MS), was initially approved at a 20-mg daily dose. Both […]

John McCorry, Senior Executive Editor for the Americas at Bloomberg News; Dorothea Pfohl, Founding Member of IOMSN; and the Knights of Columbus Santa Maria Council #1443 will be recognized by MSAA The Multiple Sclerosis Association of America (MSAA) is proud to announce their distinguished honorees for the 2018 Improving Lives Benefit scheduled for Thursday, March […]

On December 18, 2017, Novartis announced that Gilenya® (fingolimod) was granted breakthrough therapy designation by the United States Food and Drug Administration (FDA) for the treatment of children and adolescents ages 10 years or older with relapsing multiple sclerosis (MS). Known as “pediatric MS,” nearly all (98 percent) of those diagnosed experience the relapsing form […]

MSParis2017 was this year’s joint meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS). Each year, ECTRIMS hosts the world’s largest annual international conference devoted to basic and clinical research in multiple sclerosis, and every three years, ECTRIMS and […]

Free Publications Providing Extensive Information Now Available, Including the MS Relapse Toolkit and Understanding Progression in MS The Multiple Sclerosis Association of America (MSAA) has produced two new, free publications, which provide extensive information to the multiple sclerosis (MS) community on MS relapses, as well as progression in MS. The MS Relapse Toolkit is a […]

To help meet the escalating demand for MRI assistance, MSAA is pleased to announce new program changes to the MRI Access Fund, which will increase our ability to serve more clients than ever before. Qualified clients can now receive two MRI scans (brain and c-spine) per application as well as reimbursement support for previous MRI […]

On October 4, 2017, Mylan announced that two doses of their generic version of Copaxone® (glatiramer acetate) had been approved by the United States Food and Drug Administration (FDA) for relapsing forms of multiple sclerosis (MS). These two separate treatments include 40 mgs taken three-times weekly and 20 mgs taken once daily, both of which […]